REGN Technical Analysis

As of date:	10/3/2023
REGN stock price:	808.31
REGN 50 DMA:	807.51
REGN 200 DMA:	768.37
REGN MACD (200-50):	-39.14
REGN RSI:	39.29

Extremely Overbought
	39.29
Extremely Oversold

Also see:
REGN Market Cap History
REGN Shares Outstanding History
REGN YTD Return

Predict charts, win cash @ chartsweeps.com

Quotes delayed 20 minutes

Free REGN Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

LNTH Makes Bullish Cross Above Critical Moving Average
1 hour, 4 minutes ago

Tile Shop Holdings (TTSH) Shares Cross Below 200 DMA
1 hour, 6 minutes ago

Advanced Energy Industries (AEIS) Shares Cross Below 200 DMA
1 hour, 14 minutes ago

IPAR Crosses Below Key Moving Average Level
1 hour, 19 minutes ago

Notable Two Hundred Day Moving Average Cross - ORLY
1 hour, 22 minutes ago

Invesco Leisure and Entertainment Getting Very Oversold
1 hour, 24 minutes ago

Notable Two Hundred Day Moving Average Cross - PX
1 hour, 25 minutes ago

Shares of IXG Now Oversold
1 hour, 25 minutes ago

PHB Crowded With Sellers
1 hour, 25 minutes ago

iShares MSCI Mexico (EWW) Enters Oversold Territory
1 hour, 26 minutes ago

ITOT Makes Notable Cross Below Critical Moving Average
1 hour, 26 minutes ago

HYBB Crosses Critical Technical Indicator
1 hour, 26 minutes ago

HYS Getting Very Oversold
1 hour, 27 minutes ago

HYDW Enters Oversold Territory
1 hour, 27 minutes ago

RBC Bearings Breaks Below 200-Day Moving Average - Notable for RBCP
1 hour, 27 minutes ago

More Technical Analysis News

Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer.

When researching a stock like Regeneron Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from REGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for REGN stock — the real life supply and demand for the stock over time — and examines that data in different ways.

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Regeneron Pharmaceuticals (REGN) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

RMD Technical Analysis
RVTY Technical Analysis
STE Technical Analysis
SYK Technical Analysis
TECH Technical Analysis
TFX Technical Analysis
TMO Technical Analysis
UHS Technical Analysis
VRTX Technical Analysis
VTRS Technical Analysis
More Healthcare companies »

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.

REGN Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2023, All Rights Reserved